343 related articles for article (PubMed ID: 23155320)
21. Oral Treatment With Bisphosphonates of Osteoporosis Does Not Increase the Risk of Severe Gastrointestinal Side Effects: A Meta-Analysis of Randomized Controlled Trials.
Dömötör ZR; Vörhendi N; Hanák L; Hegyi P; Kiss S; Csiki E; Szakó L; Párniczky A; Erőss B
Front Endocrinol (Lausanne); 2020; 11():573976. PubMed ID: 33240217
[TBL] [Abstract][Full Text] [Related]
22. Exposure to oral bisphosphonates and risk of cancer.
Cardwell CR; Abnet CC; Veal P; Hughes CM; Cantwell MM; Murray LJ
Int J Cancer; 2012 Sep; 131(5):E717-25. PubMed ID: 22161552
[TBL] [Abstract][Full Text] [Related]
23. Bisphosphonates for osteoporosis in primary biliary cirrhosis.
Rudic JS; Giljaca V; Krstic MN; Bjelakovic G; Gluud C
Cochrane Database Syst Rev; 2011 Dec; (12):CD009144. PubMed ID: 22161446
[TBL] [Abstract][Full Text] [Related]
24. Bisphosphonates and atrial fibrillation: systematic review and meta-analysis.
Loke YK; Jeevanantham V; Singh S
Drug Saf; 2009; 32(3):219-28. PubMed ID: 19338379
[TBL] [Abstract][Full Text] [Related]
25. Oral bisphosphonates and the risk of colorectal cancer: a meta-analysis.
Yang G; Hu H; Zeng R; Huang J
J Clin Gastroenterol; 2013 Oct; 47(9):741-8. PubMed ID: 24030705
[TBL] [Abstract][Full Text] [Related]
26. Bisphosphonates for Paget's disease of bone in adults.
Corral-Gudino L; Tan AJ; Del Pino-Montes J; Ralston SH
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD004956. PubMed ID: 29192423
[TBL] [Abstract][Full Text] [Related]
27. Bisphosphonates use and risk of gastric cancer: an updated meta-analysis of cohort and case-control studies.
Cai D; Qin J; Chen G; Feng W; Liu J
Minerva Med; 2017 Oct; 108(5):464-472. PubMed ID: 28466630
[TBL] [Abstract][Full Text] [Related]
28. Pre-existing diabetes mellitus increases the risk of gastric cancer: a meta-analysis.
Yoon JM; Son KY; Eom CS; Durrance D; Park SM
World J Gastroenterol; 2013 Feb; 19(6):936-45. PubMed ID: 23429469
[TBL] [Abstract][Full Text] [Related]
29. Oral bisphosphonates and upper gastrointestinal toxicity: a study of cancer and early signals of esophageal injury.
Morden NE; Munson JC; Smith J; Mackenzie TA; Liu SK; Tosteson AN
Osteoporos Int; 2015 Feb; 26(2):663-72. PubMed ID: 25349053
[TBL] [Abstract][Full Text] [Related]
30. Bisphosphonates and other bone agents for breast cancer.
Wong MH; Stockler MR; Pavlakis N
Cochrane Database Syst Rev; 2012 Feb; (2):CD003474. PubMed ID: 22336790
[TBL] [Abstract][Full Text] [Related]
31. Oral bisphosphonate use and the risk of female breast, ovarian, and cervical cancer: a nationwide population-based cohort study.
Bae YS; Chang J; Park SM
Arch Osteoporos; 2019 Mar; 14(1):41. PubMed ID: 30888545
[TBL] [Abstract][Full Text] [Related]
32. The adverse effects of bisphosphonates in breast cancer: A systematic review and network meta-analysis.
Jackson C; Freeman ALJ; Szlamka Z; Spiegelhalter DJ
PLoS One; 2021; 16(2):e0246441. PubMed ID: 33544765
[TBL] [Abstract][Full Text] [Related]
33. Bisphosphonate therapy start may transiently increase the risk of tendon rupture in patients with glucocorticoid co-medication: a population-based observational study.
Spoendlin J; Meier C; Jick SS; Meier CR
Pharmacoepidemiol Drug Saf; 2016 Oct; 25(10):1116-1123. PubMed ID: 27297005
[TBL] [Abstract][Full Text] [Related]
34. Bisphosphonate use and the risk of breast cancer: a meta-analysis of published literature.
Liu Y; Zhao S; Chen W; Hu F; Zhu L; Zhang Q; Zhao Y
Clin Breast Cancer; 2012 Aug; 12(4):276-81. PubMed ID: 22622199
[TBL] [Abstract][Full Text] [Related]
35. Risk of atrial fibrillation among bisphosphonate users: a multicenter, population-based, Italian study.
Herrera L; Leal I; Lapi F; Schuemie M; Arcoraci V; Cipriani F; Sessa E; Vaccheri A; Piccinni C; Staniscia T; Vestri A; Di Bari M; Corrao G; Zambon A; Gregori D; Carle F; Sturkenboom M; Mazzaglia G; Trifiro G
Osteoporos Int; 2015 May; 26(5):1499-506. PubMed ID: 25752621
[TBL] [Abstract][Full Text] [Related]
36. Risk of cardiac valvulopathy with use of bisphosphonates: a population-based, multi-country case-control study.
Coloma PM; de Ridder M; Bezemer I; Herings RM; Gini R; Pecchioli S; Scotti L; Rijnbeek P; Mosseveld M; van der Lei J; Trifirò G; Sturkenboom M;
Osteoporos Int; 2016 May; 27(5):1857-67. PubMed ID: 26694594
[TBL] [Abstract][Full Text] [Related]
37. Meta-analysis: oral bisphosphonates and the risk of oesophageal cancer.
Andrici J; Tio M; Eslick GD
Aliment Pharmacol Ther; 2012 Oct; 36(8):708-16. PubMed ID: 22966908
[TBL] [Abstract][Full Text] [Related]
38. Bisphosphonate therapy for osteogenesis imperfecta.
Dwan K; Phillipi CA; Steiner RD; Basel D
Cochrane Database Syst Rev; 2016 Oct; 10(10):CD005088. PubMed ID: 27760454
[TBL] [Abstract][Full Text] [Related]
39. Fish consumption and risk of gastrointestinal cancers: a meta-analysis of cohort studies.
Yu XF; Zou J; Dong J
World J Gastroenterol; 2014 Nov; 20(41):15398-412. PubMed ID: 25386090
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
